| Literature DB >> 25768240 |
Wanxiang Li1,2, Jing Li3, Quhao Wei4, Qingfeng Hu5, Xiaowei Lin2, Mengquan Chen6, Renji Ye7, Huoyang Lv8.
Abstract
This study investigated the aminoglycoside resistance phenotypes and genotypes, as well as the prevalence of virulence genes, in Enterococcus species isolated from clinical patients in China. A total of 160 enterococcal isolates from various clinical samples collected from September 2013 to July 2014 were identified to the species level using the VITEK-2 COMPACT system. The antimicrobial susceptibilities of the identified Enterococcus strains were determined by the Kirby-Bauer (K-B) disc diffusion method. PCR-based assays were used to detect the aminoglycoside resistance and virulence genes in all enterococcal isolates. Of 160 Enterococcus isolates, 105 were identified as E. faecium, 35 as E. faecalis, and 20 isolates were classified as "other" Enterococcus species. High-level aminoglycoside resistance (HLAR) for gentamicin, streptomycin, and both antibiotics was identified in 58.8, 50, and 34.4% of strains, respectively. The most common virulence gene (50.6% of isolates) was efaA, followed by asa1 (28.8%). The most prevalent aminoglycoside resistance genes were aac(6')-Ie-aph(2''), aph(2')-Id, aph(3')-IIIa, and ant(6')-Ia, present in 49.4%, 1.3%, 48.8% and 31.3% of strains, respectively. Overall, E. faecium and E. faecalis were most frequently associated with hospital-acquired enterococcal infections in Zhejiang Province. All aminoglycoside resistance genes, except aph(2'')-Id, were significantly more prevalent in HLAR strains than amongst high level aminoglycoside susceptible (HLAS) strains, while there was no significant difference between HLAR and HLAS strains in regard to the prevalence of virulence genes, apart from esp, therefore, measures should be taken to manage infections caused by multi-drug resistant Enterococcus species.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25768240 PMCID: PMC4377949 DOI: 10.3390/ijerph120303014
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
PCR primers used in the amplification of virulence and resistance genes.
| Gene | Description | Sequence(5
| Amplicon Size (bp) | Ref. |
|---|---|---|---|---|
|
| Collagen-binding protein | GGAATGACCGAGAACGATGGC | 616 | [ |
| GCTTGATGTTGGCCTGCTTCCG | ||||
|
| Aggregation substance | CACGCTATTACGAACTATGA | 375 | [ |
| TAAGAAAGAACATCACCACGA | ||||
|
| Cytolysin | ACTCGGGGATTGATAGGC | 688 | [ |
| GCTGCTAAAGCTGCGCTT | ||||
|
| Endocarditis antigen | CGTGAGAAAGAAATGGAGGA | 499 | [ |
| CTACTAACACGTCACGAATG | ||||
|
| Enterococcal surface protein | AGATTTCATCTTTGATTCTTGG | 510 | [ |
| AATTGATTCTTTAGCATCTGG | ||||
|
| Gelatinase | TATGACAATGCTTTTTGGGAT | 213 | [ |
| AGATGCACCCGAAATAATATA | ||||
|
| Hyaluronidase | ACAGAAGAGCTGCAGGAAATG | 276 | [ |
| GACTGACGTCCAAGTTTCCAA | ||||
|
| AAC(6 | AGGAATTTATCGAAAATGGTAGAAAAG | 369 | [ |
| CACAATCGACTAAAGAGTACCAATC | ||||
|
| APH(3 | GGCTAAAATGAGAATATCACCGG | 523 | [ |
| CTTTAAAAAATCATACAGCTCGCG | ||||
|
| ANT(4 | CAAACTGCTAAATCGGTAGAAGCC | 294 | [ |
| GGAAAGTTGACCAGACATTACGAACT | ||||
|
| APH(2 | CCACAATGATAATGACTCAGTTCCC | 444 | [ |
| CCACAGCTTCCGATAGCAAGAG | ||||
|
| APH(2 | CTTGGACGCTGAGATATATGAGCAC | 867 | [ |
| GTTTGTAGCAATTCAGAAACACCCTT | ||||
|
| APH(2 | GGTGGTTTTTACAGGAATGCCATC | 642 | [ |
| CCCTCTTCATACCAATCCATATAACC | ||||
|
| ANT(3 | CACGCTATTACGAACTATGA | 284 | [ |
| TAAGAAAGAACATCACCACGA | ||||
|
| ANT(6 | ACTCGGGGATTGATAGGC | 597 | [ |
| GCTGCTAAAGCTGCGCTT |
Antibiotic susceptibility profiles of the tested Enterococcus species.
| Anti-Microbial Agent | HLAR (119) | HLAS (41) |
|
|
|
| ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R | I | S | R | I | S | R | I | S | R | I | S | R | I | S | R | I | S | |||||
| AMP * | 80 (97.6) | 0 (0) | 2 (2.4) | 1 (3.7) | 0 (0) | 26 (96.3) | 2 (20) | 0 (0) | 8 (80) | 22 (95.7) | 0 (0) | 1 (4.3) | 0 (0) | 0 (0) | 8 (100) | 3 (30) | 0 (0) | 7 (70) | 0.00 | 0.00 | 1.00 | 1.00 |
| G * | 80 (97.6) | 0 (0) | 2 (2.4) | 1 (3.7) | 0 (0) | 26 (96.3) | 2 (20) | 0 (0) | 8 (80) | 22 (95.7) | 0 (0) | 1 (4.3) | 0 (0) | 0 (0) | 8 (100) | 1 (10) | 0 (0) | 9 (90) | 0.00 | 0.00 | 1.00 | 1.00 |
| LEF * | 80 (97.6) | 0 (0) | 2 (2.4) | 15 (55.6) | 0 (0) | 12 (44.4) | 7 (70) | 0 (0) | 3 (30) | 23 (100) | 0 (0) | 0 (0) | 2 (25) | 0 (0) | 6 (75) | 3 (30) | 0 (0) | 7 (70) | 0.00 | 0.00 | 1.00 | 0.26 |
| ERY * | 80 (97.6) | 0 (0) | 2 (2.4) | 23 (85.2) | 3 (11.1) | 1 (3.7) | 9 (90) | 0 (0) | 1 (10) | 18 (78.3) | 4 (17.4) | 1 (4.3) | 2 (25) | 3 (37.5) | 3 (37.5) | 8 (80) | 1 (10) | 1 (10) | 1.00 | 0.07 | 1.00 | 0.04 |
| CIP * | 80 (97.6) | 0 (0) | 2 (2.4) | 15 (55.6) | 4 (14.8) | 8 (29.6) | 8 (80) | 1 (10) | 1 (10) | 23 (100) | 0 (0) | 0 (0) | 1 (12.5) | 2 (25) | 5 (62.5) | 3 (30) | 2 (20) | 5 (50) | 0.00 | 0.00 | 1.00 | 0.20 |
| LZD * | 3 (3.7) | 0 (0) | 79 (96.3) | 0 (0) | 0 (0) | 27 (100) | 0 (0) | 0 (0) | 10 (100) | 0 (0) | 0 (0) | 23 (100) | 0 (0) | 0 (0) | 8 (100) | 0 (0) | 0 (0) | 10 (100) | 0.57 | -- | 0.82 | -- |
| Q/D * | 8 (9.8) | 6 (7.3) | 68 (82.9) | -- | -- | -- | 7 (70) | 2 (20) | 1 (10) | 3 (13.0) | 2 (8.7) | 18 (78.3) | -- | -- | -- | 5 (50) | 2 (20) | 3 (30) | -- | -- | 0.84 | -- |
| TET * | 36 (43.9) | 1 (1.2) | 45 (54.9) | 20 (74.1) | 1 (3.7) | 6 (22.2) | 10 (100) | 0 (0) | 0 (0) | 12 (52.2) | 0 (0) | 11 (47.8) | 4 (50) | 0 (0) | 4 (50) | 8 (80) | 0 (0) | 2 (20) | 0.00 | 1.00 | 0.55 | 0.27 |
| RIF * | 64 (78.1) | 7 (8.5) | 11 (13.4) | 8 (29.6) | 5 (18.5) | 14 (51.9) | 1 (10) | 0 (0) | 9 (90) | 16 (69.6) | 5 (21.7) | 2 (8.7) | 1 (12.5) | 1 (12.5) | 6 (75) | 3 (30) | 0 (0) | 7 (70) | 0.00 | 0.00 | 0.80 | 0.45 |
| CHL * | 4 (4.9) | 3 (3.7) | 75 (91.5) | 2 (7.4) | 0 (0) | 25 (92.6) | 0 (0) | 1 (10) | 9 (90) | 1 (4.3) | 1 (4.3) | 21 (91.4) | 1 (12.5) | 1 (12.5) | 6 (75) | 0 (0) | 0 (0) | 10 (100) | 1.00 | 0.57 | 1.00 | 0.46 |
| TEC * | 15 (18.3) | 18 (22.0) | 49 (59.7) | 0 (0) | 1 (3.7) | 26 (96.3) | 0 (0) | 0 (0) | 10 (100) | 1 (4.3) | 1 (4.3) | 21 (91.4) | 1 (12.5) | 0 (0) | 7 (87.5) | 0 (0) | 0 (0) | 10 (100) | 0.00 | 1.00 | 0.00 | 0.94 |
| VAN * | 43 (52.4) | 0 (0) | 39 (47.6) | 2 (7.4) | 1 (3.7) | 24 (88.9) | 0 (0) | 0 (0) | 10 (100) | 2 (8.7) | 0 (0) | 21 (91.3) | 1 (12.5) | 0 (0) | 7 (87.5) | 0 (0) | 0 (0) | 10 (100) | 0.00 | 1.00 | 0.00 | 1.00 |
AMP (ampicillin); G (penicillins); LEF (levofloxacin); ERY (erythromycin); CIP (ciprofloxacin); LZD (linezolid); Q/D (quinupristin-dalfopristin); TET (tetracycline); RIF (rifampin); CHL (chloramphenicol); TEC (teicoplanin); VAN (vancomycin). P In HLAR strains compares E.faecium with E.faecalis. P compare E.faecium with E.faecalis. P Compare HLAR E.faecium with HLAS E.faecium. P Compare HLAR E.faecalis with HLAS E.faecalis.
Frequency of different virulence genes in Enterococcus species.
| No.of Isolates | Phenotype | Genotype | No.of Virulence Genes | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| ||
| 22 | R* | + | 4 | 9 | 1 | 12 | 5 | 4 | 3 | |||
| 10 | R | + | 2 | 2 | 5 | 7 | 3 | 4 | 4 | |||
| 7 | R | + | + | 1 | 4 | 0 | 5 | 1 | 1 | 1 | ||
| 2 | R | + | + | 0 | 0 | 0 | 1 | 0 | 0 | 0 | ||
| 15 | R | + | + | 7 | 4 | 7 | 6 | 5 | 7 | 7 | ||
| 2 | R | + | + | + | 0 | 2 | 0 | 0 | 0 | 0 | 0 | |
| 32 | R | + | + | + | 1 | 13 | 1 | 28 | 4 | 2 | 3 | |
| 29 | R | 4 | 2 | 9 | 8 | 5 | 7 | 7 | ||||
| total | 119 | 19 | 36 | 23 | 67 | 23 | 25 | 25 | ||||
| 9 | S * | + | 0 | 3 | 0 | 5 | 2 | 0 | 0 | |||
| 6 | S | + | 1 | 2 | 3 | 2 | 1 | 2 | 1 | |||
| 5 | S | + | + | 0 | 2 | 2 | 0 | 2 | 1 | 1 | ||
| 1 | S | + | + | 1 | 0 | 0 | 1 | 0 | 1 | 1 | ||
| 20 | S | 3 | 3 | 3 | 6 | 7 | 4 | 3 | ||||
| total | 41 | 5 | 10 | 8 | 14 | 12 | 8 | 6 | ||||
Notes: + = positive. R (resistance); S (susceptible).
Figure 1Frequency of different virulence and resistance genes in Enterococcus species.